share_log

Cantor Fitzgerald Initiates Coverage On Capricor Therapeutics With Overweight Rating, Announces Price Target of $8

Cantor Fitzgerald Initiates Coverage On Capricor Therapeutics With Overweight Rating, Announces Price Target of $8

坎託·菲茨傑拉德以增持評級啓動對Capricor Therapeutics的報道,宣佈目標股價爲8美元
Benzinga ·  01/05 10:31

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Overweight rating and announces Price Target of $8.

坎託·菲茨傑拉德分析師克里斯汀·克魯斯卡以增持評級開始對Capricor Therapeutics(納斯達克股票代碼:CAPR)進行報道,並宣佈目標股價爲8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論